CMRX:NSD-Chimerix, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 9.81

Change

-0.86 (-8.06)%

Market Cap

USD 0.76B

Volume

1.08M

Average Target Price

USD 13.00 (+32.52%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+6.43 (+4.33%)

USD58.72B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.43 (-0.20%)

USD55.37B 20.70 14.64
REGN Regeneron Pharmaceuticals, Inc

-2.62 (-0.58%)

USD48.55B 14.85 12.06
ALXN Alexion Pharmaceuticals, Inc

-0.90 (-0.59%)

USD33.78B 56.49 34.28
BGNE BeiGene, Ltd

-9.73 (-2.95%)

USD29.41B N/A N/A
RPRX Royalty Pharma plc

-0.45 (-0.96%)

USD28.55B 22.60 14.73
BNTX BioNTech SE

-3.30 (-2.94%)

USD27.49B -99,999.99 N/A
SGEN Seagen Inc

+1.02 (+0.68%)

USD27.19B 44.54 41.48
GMAB Genmab A/S

+0.19 (+0.56%)

USD23.40B 26.59 3.51
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CMRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 103.11% 94% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 103.11% 94% A 95% A
Trailing 12 Months  
Capital Gain 454.24% 96% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 454.24% 96% A 96% A
Trailing 5 Years  
Capital Gain 107.84% 69% D+ 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 107.84% 69% D+ 65% D
Average Annual (5 Year Horizon)  
Capital Gain 4.21% 46% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.21% 45% F 47% F
Risk Return Profile  
Volatility (Standard Deviation) 80.99% 32% F 15% F
Risk Adjusted Return 5.20% 42% F 36% F
Market Capitalization 0.76B 64% D 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 8.94 34% F 24% F
Price / Cash Flow Ratio -10.13 51% F 72% C-
EV/EBITDA 0.23 60% D- 94% A
Management Effectiveness  
Return on Equity -36.24% 72% C- 28% F
Return on Invested Capital -80.67% 35% F 12% F
Return on Assets -20.70% 65% D 19% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.75 73% C 71% C-
Short Percent 1.38% 88% B+ 73% C
Beta 1.65 39% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.